Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167469 | 0.91 | EPHX1 (0.38) | EPHX1TRPM8TRPA1CYP19A1ALDH1A1 | |
| SCHEMBL29029157 | 0.89 | EPHX1 (0.43) | EPHX1TRPM8TRPA1CYP19A1ALDH1A1 | |
| SCHEMBL9474169 | 0.74 | EPHX1 (0.50) | EPHX1TRPM8TRPA1CYP19A1ALDH1A1 | |
| SCHEMBL9508470 | 0.72 | TRPM8 (0.41) | EPHX1TRPM8TRPA1CYP19A1ALDH1A1 | |
| SCHEMBL10859209 | 0.71 | OPRM1 (0.39) | EPHX1TRPM8TRPA1ALDH1A1MEN1 | |
| SCHEMBL537561 | 0.71 | EPHX1 (0.48) | EPHX1TRPM8CYP19A1ALDH1A1HPGD | |
| SCHEMBL536647 | 0.71 | EPHX1 (0.48) | EPHX1TRPM8CYP19A1ALDH1A1HPGD | |
| SCHEMBL29157263 | 0.70 | CYP19A1 (0.54) | EPHX1CYP19A1ALDH1A1HPGDMEN1 | |
| SCHEMBL29007136 | 0.70 | TRPM8 (0.43) | EPHX1TRPM8TRPA1CYP19A1ALDH1A1 | |
| SCHEMBL28431018 | 0.70 | TRPM8 (0.46) | EPHX1TRPM8TRPA1CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203776-A1 | METHODS OF USING MENTHOL PROPYLENEGLYCOL-CARBONATE AND ANALOGS THEREOF FOR PRODUCING ANTI-INFLAMMATORY AND ANTI-ANGIOGENIC EFFECTS | MATIAS JONATHAN R | 2009-08-13 | — | — | US | claimed |
| WO-2006034495-A2 | METHODS OF USING MENTHOL PROPYLENEGLYCOL-CARBONATE AND ANALOGS THEREOF FOR PRODUCING ANTI-INFLAMMATORY AND ANTI-ANGIOGENIC EFFECTS | MATIAS JONATHAN R (US) | 2006-03-30 | — | — | WO | claimed |
| US-20090203776-A1 | METHODS OF USING MENTHOL PROPYLENEGLYCOL-CARBONATE AND ANALOGS THEREOF FOR PRODUCING ANTI-INFLAMMATORY AND ANTI-ANGIOGENIC EFFECTS | MATIAS JONATHAN R | 2009-08-13 | — | — | US | disclosed |
| WO-2006034495-A2 | METHODS OF USING MENTHOL PROPYLENEGLYCOL-CARBONATE AND ANALOGS THEREOF FOR PRODUCING ANTI-INFLAMMATORY AND ANTI-ANGIOGENIC EFFECTS | MATIAS JONATHAN R (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203776-A1 | METHODS OF USING MENTHOL PROPYLENEGLYCOL-CARBONATE AND ANALOGS THEREOF FOR PRODUCING ANTI-INFLAMMATORY AND ANTI-ANGIOGENIC EFFECTS | PTGIS, CAPG, PTGES | EPHX1 1032/4885TRPM8 222/4885TRPA1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.